Northstar Response^®

Northstar Response is a tissue-free, methylation-based assay that enables real-time monitoring with single-molecule precision—detecting subtle shifts in tumor burden at sensitivity down to 0.01% tumor fraction.

0.01% Analytical limit of detection
>2,200 Gene sites targeted for methylation analysis

Cancer doesn't wait.
You need an assay that can stay ahead.Enhance treatment monitoring with real-time tumor tracking and epigenomic insights from a simple blood draw—enabling earlier, more confident decisions.
‍

• Pan-cancer and treatment agnostic response monitoring
• >2,200 targeted methylation loci
• Limit of detection down to 0.01% tumor fraction for extreme sensitivity
• Quantitative Tumor Methylation Score (TMS)
• Longitudinal tracking of therapy response

Tumor Methylation versus SNV- / Methylation-based monitoring tests
Tumor methylation is a robust, tumor-specific biomarker that overcomes the limitations of tracking only variant allele fractions (VAF) from a few somatic mutations, as in first-generation ctDNA assays. As a liquid-only test, it requires no tissue and avoids the delays and complexity of tumor-informed approaches— delivering faster insights into treatment response.

A convenient complement to imaging
Tumor methylation is a robust, tumor-specific biomarker that overcomes the limitations of tracking only variant allele fractions (VAF) from a few somatic mutations, as in first-generation ctDNA assays. As a liquid-only test, it requires no tissue and avoids the delays and complexity of tumor-informed approaches— delivering faster insights into treatment response.

More timely insights to optimize treatment strategy
Northstar Response® helps optimize treatment strategy by delivering early, actionable signals—often before imaging alone.
‍

• Track response between scans
  Get real-time feedback on therapy effectiveness without waiting for the next imaging cycle—helping you stay one step ahead.
• Clarify imaging results
  Use molecular signals to support decision-making when imaging results are unclear or confounded by pseudo-progression or inflammation.
• Adapt to changes sooner
  Detect subtle changes in tumor burden earlier than traditional tools, allowing for more timely treatment adjustments or escalation.

The only tissue-free treatment monitoring test that achieves single-molecule precision.More timely insights to optimize treatment strategy

Clear and intuitive reportingMore timely insights to optimize treatment strategy
The Northstar Response report was designed to easily convey longitudinal monitoring tumor burden trends for patients on systemic treatment (chemotherapy, immunotherapy, targeted therapy).
‍

• Clear result indicators: categorizes whether tumor burden increased, decreased, or remained stable
• Precise Tumor Methylation Score™ (TMS): quantifies tumor burden in each sample
• Graphical TMS trend: Easily identify trends between collections